AstraZeneca hyperkalemia therapy gets EU approval

AstraZeneca plc (LSE:AZN; NYSE:AZN) said the European Commission approved its MAA for Lokelma sodium zirconium cyclosilicate (ZS-9) to treat hyperkalemia in adults. An AZ spokesperson told BioCentury the pharma expects to launch Lokelma this year, but declined to give timing or pricing details.

Lokelma is an inorganic crystal form of zirconium silicate designed to trap potassium ions over other ions throughout the GI tract...